TD Cowen raised the firm’s price target on Elevance Health to $585 from $564 and keeps an Outperform rating on the shares. The firm said the 2023 commercial repricing thesis is manifest and company’s below-market MA enrollment growth increasingly appears to reflect prudent bid conservatism; both of which suggest relative outperformance versus the managed care group in 2H23.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELV:
- Early notable gainers among liquid option names on July 19th
- Elevance (NYSE:ELV) Pops on Q2 Beat; Guidance Impresses
- Elevance Health reports Medical enrollment of 48M members
- Elevance Health raises FY23 adjusted EPS view to greater than $32.85 per share
- Elevance Health reports Q2 adjusted EPS $9.04, consensus $8.80